Daiichi Sankyo Company, Limited

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 12/03/2026 pm IST			5-day change	1st Jan Change
2,900.00 ^JPY	+1.59%		+1.97%	-13.38%

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
09/03	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT

Daiichi Sankyo Company, Limited Reports Earnings Results for the Nine Months Ended December 31, 2025

Published on 01/30/2026 at 09:30 am IST

S&P Capital IQ

DAIICHI SANKYO COMPANY, LIMITED

+1.59%

Daiichi Sankyo Company, Limited reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 1,533,459 million compared to JPY 1,367,567 million a year ago. Net income was JPY 217,446 million compared to JPY 208,603 million a year ago.

Basic earnings per share from continuing operations was JPY 117.34 compared to JPY 109.65 a year ago. Diluted earnings per share from continuing operations was JPY 117.28 compared to JPY 109.58 a year ago.

Latest news about Daiichi Sankyo Company, Limited

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
09/03	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT
09/03	Astra drug wins US review as oil surges above USD100	AN
09/03	AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer	MT
09/03	Daiichi Sankyo says Enhertu gets U.S. Priority Review for HER2-positive early breast cancer	RE
09/03	AstraZeneca and Daiichi secure US fast-track status for cancer drug	AN
09/03	AstraZeneca, Daiichi Sankyo's Enhertu Receives US FDA Priority Review Status in Early Breast Cancer	MT
09/03	Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer	CI
27/02	Daiichi Sankyo Submits Supplemental New Drug Application for Enhertu as Adjuvant Therapy for Her2 Positive Early Breast Cancer in Japan	CI
26/02	Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026	CI
26/02	Daiichi Sankyo Company, Limited Announces Retirement of Sunao Manabe as Representative Director Executive Chairperson, Effective February 26, 2026	CI
24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT
24/02	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
24/02	Daiichi Sankyo Company, Limited Announces Executive Changes Effective from April 1, 2026	CI

Chart Daiichi Sankyo Company, Limited

Duration

Period

4568: Dynamic Chart

Company Profile

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Employees

19,765

Sector

Pharmaceuticals

Calendar

30/03 - Ex-dividend date - 39 JPY

More about the company